Published in Clin Endocrinol (Oxf) on October 01, 2006
Lesion dose in differentiated thyroid carcinoma metastases after rhTSH or thyroid hormone withdrawal: 124I PET/CT dosimetric comparisons. Eur J Nucl Med Mol Imaging (2010) 1.61
Expanding indications for recombinant human TSH in thyroid cancer. Thyroid (2008) 1.49
Recombinant human TSH in differentiated thyroid cancer: a nuclear medicine perspective. Eur J Nucl Med Mol Imaging (2008) 1.42
Radioiodine treatment of metastatic thyroid cancer: relative efficacy and side effect profile of preparation by thyroid hormone withdrawal versus recombinant human thyrotropin. Thyroid (2012) 0.90
Single photon emission computed tomography imaging for temporal dynamics of thyroidal and salivary radionuclide accumulation in 17-allyamino-17-demothoxygeldanamycin-treated thyroid cancer mouse model. Endocr Relat Cancer (2010) 0.85
Potential use of recombinant human thyrotropin in the treatment of distant metastases in patients with differentiated thyroid cancer. Endocr Pract (2013) 0.80
On the effectiveness of recombinant human TSH as a stimulating agent for 131I treatment of metastatic differentiated thyroid cancer. Eur J Nucl Med Mol Imaging (2010) 0.77
What role for recombinant human TSH in the treatment of metastatic thyroid cancer? Eur J Nucl Med Mol Imaging (2009) 0.77
Treatment of distant metastases from follicular cell-derived thyroid cancer. F1000Prime Rep (2015) 0.75
Role of Recombinant Human Thyrotropin (rhTSH) in the Treatment of Well-Differentiated Thyroid Cancer. Indian J Surg Oncol (2011) 0.75
Recombinant human thyroid stimulating hormone in 2008: focus on thyroid cancer management. Onco Targets Ther (2009) 0.75
Recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal in 124I-PET/CT based dosimetry for 131I therapy of metastatic differentiated thyroid cancer. J Nucl Med (2017) 0.75
No immunological benefit of selenium in consecutive patients with autoimmune thyroiditis. Thyroid (2008) 2.26
Frequency and relevance of elevated calcitonin levels in patients with neoplastic and nonneoplastic thyroid disease and in healthy subjects. J Clin Endocrinol Metab (2004) 1.92
FDG PET is superior to CT in the prediction of viable tumour in post-chemotherapy seminoma residuals. Eur J Radiol (2005) 1.70
2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol (2004) 1.69
Intraoperative tissue fluorescence using 5-aminolevolinic acid (5-ALA) is more sensitive than contrast MRI or amino acid positron emission tomography ((18)F-FET PET) in glioblastoma surgery. Neurol Res (2012) 1.67
In vitro and in vivo evaluation of [18F]ciprofloxacin for the imaging of bacterial infections with PET. Eur J Nucl Med Mol Imaging (2004) 1.67
Uptake of bone-seekers is solely associated with mineralisation! A study with 99mTc-MDP, 153Sm-EDTMP and 18F-fluoride on osteoblasts. Eur J Nucl Med Mol Imaging (2006) 1.65
Visualisation of the lymph node pathway in real time by laparoscopic radioisotope- and fluorescence-guided sentinel lymph node dissection in prostate cancer staging. Urology (2012) 1.64
Pharmacoresistance in epilepsy: a pilot PET study with the P-glycoprotein substrate R-[(11)C]verapamil. Epilepsia (2007) 1.55
The serotonin-1A receptor distribution in healthy men and women measured by PET and [carbonyl-11C]WAY-100635. Eur J Nucl Med Mol Imaging (2008) 1.55
Long-term follow-up of patients with bone metastases from differentiated thyroid carcinoma -- surgery or conventional therapy? Clin Endocrinol (Oxf) (2002) 1.53
[11C] methionine and [18F] fluorodeoxyglucose PET in the follow-up of glioblastoma multiforme. J Neurooncol (2007) 1.51
Coronary vasoreactivity in subjects with thyroid autoimmunity and subclinical hypothyroidism before and after supplementation with thyroxine. Thyroid (2012) 1.39
Brain tumour imaging with PET: a comparison between [18F]fluorodopa and [11C]methionine. Eur J Nucl Med Mol Imaging (2003) 1.23
Antibiotic abscess penetration: fosfomycin levels measured in pus and simulated concentration-time profiles. Antimicrob Agents Chemother (2005) 1.22
Differential modulation of the default mode network via serotonin-1A receptors. Proc Natl Acad Sci U S A (2012) 1.22
Influence of functional haplotypes in the drug transporter gene ABCB1 on central nervous system drug distribution in humans. Clin Pharmacol Ther (2005) 1.19
Electromagnetic navigation bronchoscopy in combination with PET-CT and rapid on-site cytopathologic examination for diagnosis of peripheral lung lesions. Lung (2008) 1.18
Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET. J Nucl Med (2004) 1.12
Positron emission tomography imaging of adrenal masses: (18)F-fluorodeoxyglucose and the 11beta-hydroxylase tracer (11)C-metomidate. Eur J Nucl Med Mol Imaging (2004) 1.09
Positron emission tomography with [18F] 2-fluoro-D-2- deoxyglucose in primary cutaneous T-cell lymphomas. Haematologica (2004) 1.07
Psychometric- and quality-of-life assessment in long-term glioblastoma survivors. J Neurooncol (2003) 1.07
Diagnostic imaging in Merkel cell carcinoma: lessons to learn from 16 cases with correlation of sonography, CT, MRI and PET. Eur J Radiol (2008) 1.06
Quality of life in patients with non-metastatic differentiated thyroid cancer under thyroxine supplementation therapy. Support Care Cancer (2003) 1.02
The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT. Mol Imaging Biol (2009) 1.02
Cervical anterior transpedicular screw fixation (ATPS)--Part II. Accuracy of manual insertion and pull-out strength of ATPS. Eur Spine J (2008) 1.01
11C-acetate positron emission tomography imaging and image fusion with computed tomography and magnetic resonance imaging in patients with recurrent prostate cancer. J Clin Oncol (2006) 1.01
The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT. Mol Imaging Biol (2009) 1.00
Increased prevalence of sublinical brain perfusion abnormalities in patients with autoimmune thyroiditis: evidence of Hashimoto's encephalitis? Clin Endocrinol (Oxf) (2003) 0.99
Assessment of myocardial perfusion by dynamic N-13 ammonia PET imaging: comparison of 2 tracer kinetic models. J Nucl Cardiol (2005) 0.99
PET based volume segmentation with emphasis on the iterative TrueX algorithm. Z Med Phys (2011) 0.99
Isotopic renal function studies in severe hypothyroidism and after thyroid hormone replacement therapy. Am J Nephrol (2003) 0.98
18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) for staging and follow-up of marginal zone B-cell lymphoma. Oncology (2003) 0.97
What affects the recurrence and clinical outcome of pigmented villonodular synovitis? Clin Orthop Relat Res (2006) 0.96
Combining image-derived and venous input functions enables quantification of serotonin-1A receptors with [carbonyl-11C]WAY-100635 independent of arterial sampling. Neuroimage (2012) 0.95
Preparation and first evaluation of [(18)F]FE@SUPPY: a new PET tracer for the adenosine A(3) receptor. Nucl Med Biol (2008) 0.93
Differences in the dynamics of serotonin reuptake transporter occupancy may explain superior clinical efficacy of escitalopram versus citalopram. Int Clin Psychopharmacol (2009) 0.92
Chronic heart failure leads to an expanded plasma volume and pseudoanaemia, but does not lead to a reduction in the body's red cell volume. Eur Heart J (2008) 0.90
Combined PET and microdialysis for in vivo assessment of intracellular drug pharmacokinetics in humans. J Nucl Med (2005) 0.90
11C-methionine PET/CT imaging of 99mTc-MIBI-SPECT/CT-negative patients with primary hyperparathyroidism and previous neck surgery. J Clin Endocrinol Metab (2014) 0.90
Prediction of SSRI treatment response in major depression based on serotonin transporter interplay between median raphe nucleus and projection areas. Neuroimage (2012) 0.90
Targeting CD20 in melanoma patients at high risk of disease recurrence. Mol Ther (2012) 0.89
The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT. Eur Radiol (2009) 0.89
Comparison of (11)C-acetate positron emission tomography and (67)Gallium citrate scintigraphy in patients with hepatocellular carcinoma. Liver Int (2006) 0.89
Higher serotonin transporter occupancy after multiple dose administration of escitalopram compared to citalopram: an [123I]ADAM SPECT study. Psychopharmacology (Berl) (2007) 0.89
Assessment of pulmonary melanoma metastases with 18F-FDG PET/CT: which PET-negative patients require additional tests for definitive staging? Eur Radiol (2012) 0.88
Pre vivo, ex vivo and in vivo evaluations of [68Ga]-EDTMP. Nucl Med Biol (2007) 0.88
Rapid detection of bone metastasis at thoracoabdominal CT: accuracy and efficiency of a new visualization algorithm. Radiology (2013) 0.87
Typical chest pain and normal coronary angiogram: cardiac risk factor analysis versus PET for detection of microvascular disease. J Nucl Med (2007) 0.87
Microfluidic preparation of [18F]FE@SUPPY and [18F]FE@SUPPY:2--comparison with conventional radiosyntheses. Nucl Med Biol (2010) 0.87
A positron emission tomography microdosing study with a potential antiamyloid drug in healthy volunteers and patients with Alzheimer's disease. Clin Pharmacol Ther (2006) 0.87
Evaluating repetitive 18F-fluoroazomycin-arabinoside (18FAZA) PET in the setting of MRI guided adaptive radiotherapy in cervical cancer. Acta Oncol (2010) 0.86
Electromechanical properties of perfusion/metabolism mismatch: comparison of nonfluoroscopic electroanatomic mapping with 18F-FDG PET. J Nucl Med (2004) 0.86
Relation of anti-TPO autoantibody titre and T-lymphocyte cytokine production patterns in Hashimoto's thyroiditis. Clin Endocrinol (Oxf) (2005) 0.86
Long-term impairment of the lacrimal glands after radioiodine therapy: a cross-sectional study. Eur J Nucl Med Mol Imaging (2002) 0.85
Different pattern of regional metabolic abnormalities in Takotsubo cardiomyopathy as evidenced by F-18 FDG PET-CT. Wien Klin Wochenschr (2010) 0.84
[¹⁸F]FE@SNAP-A new PET tracer for the melanin concentrating hormone receptor 1 (MCHR1): microfluidic and vessel-based approaches. Bioorg Med Chem (2012) 0.84
The stability of methyl-, ethyl- and fluoroethylesters against carboxylesterases in vitro: there is no difference. Nucl Med Biol (2010) 0.83
Molecular Imaging in Breast Cancer - Potential Future Aspects. Breast Care (Basel) (2011) 0.83
Radiolabeling of [18F]altanserin - a microfluidic approach. Nucl Med Biol (2012) 0.83
Tc-99m-labeled human polyclonal immunoglobulin G (HIG) scintigraphy in Sjögren's syndrome. Scand J Rheumatol (2002) 0.82
[18F]Ciprofloxacin, a new positron emission tomography tracer for noninvasive assessment of the tissue distribution and pharmacokinetics of ciprofloxacin in humans. Antimicrob Agents Chemother (2004) 0.82
Glucose acts as a regulator of serum iron by increasing serum hepcidin concentrations. J Nutr Biochem (2012) 0.82
Striatal D(2) receptor occupancy in bipolar patients treated with olanzapine. Eur Neuropsychopharmacol (2006) 0.82
Myocardial involvement in a patient with Burkitt's lymphoma mimicking hypertrophic cardiomyopathy. J Am Soc Echocardiogr (2003) 0.81
[18F]FE@SUPPY and [18F]FE@SUPPY:2--metabolic considerations. Nucl Med Biol (2010) 0.81
Biological evaluation of 2'-[18F]fluoroflumazenil ([18F]FFMZ), a potential GABA receptor ligand for PET. Nucl Med Biol (2004) 0.81
New aspects on the preparation of [11C]Methionine--a simple and fast online approach without preparative HPLC. Appl Radiat Isot (2005) 0.81
Are contrast media required for (68)Ga-DOTATOC PET/CT in patients with neuroendocrine tumours of the abdomen? Eur Radiol (2011) 0.80
Radiation synovectomy with (166)Ho-ferric hydroxide: a first experience. J Nucl Med (2002) 0.80
FDG positron emission tomography in patients with systemic mastocytosis. AJR Am J Roentgenol (2002) 0.80
18F fluoroethylations: different strategies for the rapid translation of 11C-methylated radiotracers. Nucl Med Biol (2007) 0.80
[18F]FETO for adrenocortical PET imaging: a pilot study in healthy volunteers. Eur J Nucl Med Mol Imaging (2006) 0.80
Different types of resistance training in type 2 diabetes mellitus: effects on glycaemic control, muscle mass and strength. Eur J Prev Cardiol (2012) 0.79
The presence of MOMA-2+ macrophages in the outer B cell zone and protection of the splenic micro-architecture from LPS-induced destruction depend on secreted IgM. Eur J Immunol (2007) 0.79
Measurement of calcitonin by immunoassay analyzers. Clin Chem Lab Med (2007) 0.79